Anti-proliferative effect and action mechanism of dexamethasone in human medullary thyroid cancer cell line

Endocrine Research

Volumn 36, Issue 4, 2011, Pages 149-157

  Chung, Yun Jae ^a   Lee, Ji In ^a   Chong, Semin ^a   Seok, Ju Won ^a   Park, Sung Jun ^a   Jang, Hye Won ^b   Kim, Sun Wook ^b   Chung, Jae Hoon ^b  

^a Chung Ang University   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Apoptosis; Cell cycle arrest; Dexamethasone; Medullary thyroid carcinoma; TT cells

Indexed keywords

BROXURIDINE; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; DEXAMETHASONE; DNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; RETINOBLASTOMA PROTEIN;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; THYROID MEDULLARY CARCINOMA;

APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, MEDULLARY; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DEXAMETHASONE; FLOW CYTOMETRY; GLUCOCORTICOIDS; HUMANS; THYROID NEOPLASMS;

EID: 80053619336     PISSN: 07435800     EISSN: 15324206     Source Type: Journal    
DOI: 10.3109/07435800.2011.593012     Document Type: Article

References (19)

1. Chen H, Kunnimalaiyaan M, Van Gompel JJ. Medullary thyroid cancer: The functions of raf-1 and human achaete-scute homologue-1. Thyroid 2005;15:511-521. (Pubitemid 40993724)
2. Hundahl SA, Fleming ID, Fremgen AM, Menck HRA. National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 1998;83:2638-2648.
3. Vitale G, Caraglia M, Ciccarelli A, et al. Current approaches and perspectives in the therapy of medullary thyroid carcinoma. Cancer 2001;91:1797-1808. (Pubitemid 32377967)
4. Asai N, Iwashita T, Matsuyama M, Takahashi M. Mechanism of activation of the RET protooncogene bymultiple endocrine neoplasia 2A mutations. Mol Cell Biol 1995;15:1613-1619.
5. Santoro M, Carlomagno F, Romano A, et al. Activation of RET as a dominant transforming gene by germline mutations ofMEN2A andMEN2B. Science 1995;267:381-383.
6. Asai N, Murakami H, Iwashita T, Takahashi M. A mutation at tyrosine 1062 in MEN2A-RET and MEN2B-RET impairs their transforming activity and association with shc adaptor proteins. J Biol Chem 1996;271:17644-17649. (Pubitemid 26250733)
7. Segouffin-Cariou C, Billaud M. Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway. J Biol Chem 2000;275:3568-3576. (Pubitemid 30083066)
8. Watanabe T, Ichihara M, Hashimoto M, et al. Characterization of gene expression induced by RET with MEN2A orMEN2B mutation. Am J Pathol 2002;161:249-256. (Pubitemid 34760790)
9. FrankfurtO, Rosen ST.Mechanisms of glucocorticoid-induced apoptosis in hematologicmalignancies: Updates. Curr Opin Oncol 2004;16:553-563. (Pubitemid 39482974)
10. Yamamoto T, Nishiguchi M, Inoue N, et al. Inhibition of murine osteosarcoma cell proliferation by glucocorticoid. Anticancer Res 2002;22:4151-4156. (Pubitemid 36134448)
11. Cram EJ, Ramos RA, Wang EC, Cha HH, Nishio Y, Firestone GL. Role of the CCAAT/enhancer binding protein-alpha transcription factor in the glucocorticoid stimulation of p21waf1/cip1 gene promoter activity in growth-arrested rat hepatoma cells. J Biol Chem 1998;273:2008-2014. (Pubitemid 28069246)
12. Goya L, Maiyar AC, Ge Y, Firestone GL. Glucocorticoids induce a G1/G0 cell cycle arrest of Con8 rat mammary tumor cells that is synchronously reversed by steroid withdrawal or addition of transforming growth factor-alpha. Mol Endocrinol 1993;7:1121-1132. (Pubitemid 23285271)
13. Capes-Davis A, Andrew SD, Hyland VJ, et al. Glucocorticoids differentially inhibit expression of the RET proto-oncogene. Gene Expr 1999;8:311-326. (Pubitemid 30637490)
14. Carlomagno F, Salvatore D, Santoro M, et al. Point mutation of the RET proto-oncogene in the TT humanmedullary thyroid carcinoma cell line. Biochem Biophys Res Commun 1995;207:1022-1028.
15. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev 1998;12:2245-2262. (Pubitemid 28371346)
16. Harbour JW, Dean DC. Rb function in cell-cycle regulation and apoptosis. Nat Cell Biol 2000;2: E65-E67.
17. Dou QP, Levin AH, Zhao S, Pardee AB. Cyclin E and cyclin A as candidates for the restriction point protein. Cancer Res 1993;53:1493-1497. (Pubitemid 23113217)
18. Sherr CJ, Roberts JM. CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev 1999;13:1501-1512. (Pubitemid 29297917)
19. Resnitzky D, Hengst L, Reed SI. Cyclin A-associated kinase activity is rate limiting for entrance into S phase and is negatively regulated in G1 by p27Kip1. Mol Cell Biol 1995;15:4347-4352.